Neuropsychiatric SLE: From animal model to human
Animal models are a key element in disease research and treatment. In the field of neuropsychiatric lupus research, inbred, transgenic and disease-induced mice provide an opportunity to study the pathogenic routes of this multifactorial illness. In addition to achieving a better understanding of the...
- Autores:
- Tipo de recurso:
- Fecha de publicación:
- 2017
- Institución:
- Universidad del Rosario
- Repositorio:
- Repositorio EdocUR - U. Rosario
- Idioma:
- eng
- OAI Identifier:
- oai:repository.urosario.edu.co:10336/22543
- Acceso en línea:
- https://doi.org/10.1177/0961203317694261
https://repository.urosario.edu.co/handle/10336/22543
- Palabra clave:
- Autoantibody
Belimumab
Brain antigen
Cardiolipin antibody
Complement
Complement inhibitor
Crry ig
Cyclophosphamide
Cytokine
Fisle 412 peptide
Hcdr1 peptide
Immunoglobulin
Intercellular adhesion molecule 1 antibody
N methyl dextro aspartic acid receptor antibody
N methyl dextro aspartic acid receptor nr2 antibody
P 140 peptide
Peptide fragment
Ribosomal p antibody
Unclassified drug
Vitamin d
Autoantibody
Cytokine
Apoptosis
Article
Biological therapy
Blood brain barrier
Brain metabolism
Cell phagocytosis
Dietary supplement
Genetic susceptibility
Human
Immunoregulation
Mental disease
Murphy roths large lymphoproliferative mouse
Neuroendocrine system
Neuropsychiatric systemic lupus erythematosus
Nonhuman
Nzbxnzw f1 mouse
Pathogenesis
Priority journal
Systemic lupus erythematosus
Vaccination
Animal
Brain vasculitis
Disease model
Genetic predisposition
Genetics
Metabolism
Mouse
Pathology
Transgenic animal
Animals
Autoantibodies
Cytokines
Genetic predisposition to disease
Humans
Mice
Animal models
Lupus
Neuropsychiatric
Targeted biological medication
animal
central nervous system
genetically modified
Animals
Disease models
Lupus vasculitis
- Rights
- License
- Abierto (Texto Completo)
id |
EDOCUR2_9b57321e70008ffd54ce496d77128fb6 |
---|---|
oai_identifier_str |
oai:repository.urosario.edu.co:10336/22543 |
network_acronym_str |
EDOCUR2 |
network_name_str |
Repositorio EdocUR - U. Rosario |
repository_id_str |
|
spelling |
a8e0e1bc-3bfa-406e-895c-692260837b2a-1e0647900-20ef-41d2-a11d-fd3a007b02a0-1c654a649-7fdc-4a3e-926d-0225c4b9fff3-1232ce352-6420-4ab4-ac33-901ea6e15362-1e6b2d288-9ee7-4f09-b9ae-93d675eeb5af-14539c3bc-71d9-447d-8599-93032f5a9880-16b286b69-16c0-4eae-a12c-57f7a4b4c759-1072631a7-804c-42e7-b8d6-302682172e61-12020-05-25T23:56:51Z2020-05-25T23:56:51Z2017Animal models are a key element in disease research and treatment. In the field of neuropsychiatric lupus research, inbred, transgenic and disease-induced mice provide an opportunity to study the pathogenic routes of this multifactorial illness. In addition to achieving a better understanding of the immune mechanisms underlying the disease onset, supplementary metabolic and endocrine influences have been discovered and investigated. The ever-expanding knowledge about the pathologic events that occur at disease inception enables us to explore new drugs and therapeutic approaches further and to test them using the same animal models. Discovery of the molecular targets that constitute the pathogenic basis of the disease along with scientific advancements allow us to target these molecules with monoclonal antibodies and other specific approaches directly. This novel therapy, termed 'targeted biological medication' is a promising endeavor towards producing drugs that are more effective and less toxic. Further work to discover additional molecular targets in lupus' pathogenic mechanism and to produce drugs that neutralize their activity is needed to provide patients with safe and efficient methods of controlling and treating the disease. © The Author(s), 2016.application/pdfhttps://doi.org/10.1177/09612033176942610961203314770962https://repository.urosario.edu.co/handle/10336/22543engSAGE Publications Ltd477No. 5470LupusVol. 26Lupus, ISSN:09612033, 14770962, Vol.26, No.5 (2017); pp. 470-477https://www.scopus.com/inward/record.uri?eid=2-s2.0-85018348850&doi=10.1177%2f0961203317694261&partnerID=40&md5=764293029acc41b567156cc023ac7acaAbierto (Texto Completo)http://purl.org/coar/access_right/c_abf2instname:Universidad del Rosarioreponame:Repositorio Institucional EdocURAutoantibodyBelimumabBrain antigenCardiolipin antibodyComplementComplement inhibitorCrry igCyclophosphamideCytokineFisle 412 peptideHcdr1 peptideImmunoglobulinIntercellular adhesion molecule 1 antibodyN methyl dextro aspartic acid receptor antibodyN methyl dextro aspartic acid receptor nr2 antibodyP 140 peptidePeptide fragmentRibosomal p antibodyUnclassified drugVitamin dAutoantibodyCytokineApoptosisArticleBiological therapyBlood brain barrierBrain metabolismCell phagocytosisDietary supplementGenetic susceptibilityHumanImmunoregulationMental diseaseMurphy roths large lymphoproliferative mouseNeuroendocrine systemNeuropsychiatric systemic lupus erythematosusNonhumanNzbxnzw f1 mousePathogenesisPriority journalSystemic lupus erythematosusVaccinationAnimalBrain vasculitisDisease modelGenetic predispositionGeneticsMetabolismMousePathologyTransgenic animalAnimalsAutoantibodiesCytokinesGenetic predisposition to diseaseHumansMiceAnimal modelsLupusNeuropsychiatricTargeted biological medicationanimalcentral nervous systemgenetically modifiedAnimalsDisease modelsLupus vasculitisNeuropsychiatric SLE: From animal model to humanarticleArtículohttp://purl.org/coar/version/c_970fb48d4fbd8a85http://purl.org/coar/resource_type/c_6501Pikman R.Kivity S.Levy Y.Arango M.-T.Chapman J.Yonath H.Shoenfeld Y.Gofrit S.G.10336/22543oai:repository.urosario.edu.co:10336/225432022-05-02 07:37:14.231388https://repository.urosario.edu.coRepositorio institucional EdocURedocur@urosario.edu.co |
dc.title.spa.fl_str_mv |
Neuropsychiatric SLE: From animal model to human |
title |
Neuropsychiatric SLE: From animal model to human |
spellingShingle |
Neuropsychiatric SLE: From animal model to human Autoantibody Belimumab Brain antigen Cardiolipin antibody Complement Complement inhibitor Crry ig Cyclophosphamide Cytokine Fisle 412 peptide Hcdr1 peptide Immunoglobulin Intercellular adhesion molecule 1 antibody N methyl dextro aspartic acid receptor antibody N methyl dextro aspartic acid receptor nr2 antibody P 140 peptide Peptide fragment Ribosomal p antibody Unclassified drug Vitamin d Autoantibody Cytokine Apoptosis Article Biological therapy Blood brain barrier Brain metabolism Cell phagocytosis Dietary supplement Genetic susceptibility Human Immunoregulation Mental disease Murphy roths large lymphoproliferative mouse Neuroendocrine system Neuropsychiatric systemic lupus erythematosus Nonhuman Nzbxnzw f1 mouse Pathogenesis Priority journal Systemic lupus erythematosus Vaccination Animal Brain vasculitis Disease model Genetic predisposition Genetics Metabolism Mouse Pathology Transgenic animal Animals Autoantibodies Cytokines Genetic predisposition to disease Humans Mice Animal models Lupus Neuropsychiatric Targeted biological medication animal central nervous system genetically modified Animals Disease models Lupus vasculitis |
title_short |
Neuropsychiatric SLE: From animal model to human |
title_full |
Neuropsychiatric SLE: From animal model to human |
title_fullStr |
Neuropsychiatric SLE: From animal model to human |
title_full_unstemmed |
Neuropsychiatric SLE: From animal model to human |
title_sort |
Neuropsychiatric SLE: From animal model to human |
dc.subject.keyword.spa.fl_str_mv |
Autoantibody Belimumab Brain antigen Cardiolipin antibody Complement Complement inhibitor Crry ig Cyclophosphamide Cytokine Fisle 412 peptide Hcdr1 peptide Immunoglobulin Intercellular adhesion molecule 1 antibody N methyl dextro aspartic acid receptor antibody N methyl dextro aspartic acid receptor nr2 antibody P 140 peptide Peptide fragment Ribosomal p antibody Unclassified drug Vitamin d Autoantibody Cytokine Apoptosis Article Biological therapy Blood brain barrier Brain metabolism Cell phagocytosis Dietary supplement Genetic susceptibility Human Immunoregulation Mental disease Murphy roths large lymphoproliferative mouse Neuroendocrine system Neuropsychiatric systemic lupus erythematosus Nonhuman Nzbxnzw f1 mouse Pathogenesis Priority journal Systemic lupus erythematosus Vaccination Animal Brain vasculitis Disease model Genetic predisposition Genetics Metabolism Mouse Pathology Transgenic animal Animals Autoantibodies Cytokines Genetic predisposition to disease Humans Mice Animal models Lupus Neuropsychiatric Targeted biological medication |
topic |
Autoantibody Belimumab Brain antigen Cardiolipin antibody Complement Complement inhibitor Crry ig Cyclophosphamide Cytokine Fisle 412 peptide Hcdr1 peptide Immunoglobulin Intercellular adhesion molecule 1 antibody N methyl dextro aspartic acid receptor antibody N methyl dextro aspartic acid receptor nr2 antibody P 140 peptide Peptide fragment Ribosomal p antibody Unclassified drug Vitamin d Autoantibody Cytokine Apoptosis Article Biological therapy Blood brain barrier Brain metabolism Cell phagocytosis Dietary supplement Genetic susceptibility Human Immunoregulation Mental disease Murphy roths large lymphoproliferative mouse Neuroendocrine system Neuropsychiatric systemic lupus erythematosus Nonhuman Nzbxnzw f1 mouse Pathogenesis Priority journal Systemic lupus erythematosus Vaccination Animal Brain vasculitis Disease model Genetic predisposition Genetics Metabolism Mouse Pathology Transgenic animal Animals Autoantibodies Cytokines Genetic predisposition to disease Humans Mice Animal models Lupus Neuropsychiatric Targeted biological medication animal central nervous system genetically modified Animals Disease models Lupus vasculitis |
dc.subject.keyword.eng.fl_str_mv |
animal central nervous system genetically modified Animals Disease models Lupus vasculitis |
description |
Animal models are a key element in disease research and treatment. In the field of neuropsychiatric lupus research, inbred, transgenic and disease-induced mice provide an opportunity to study the pathogenic routes of this multifactorial illness. In addition to achieving a better understanding of the immune mechanisms underlying the disease onset, supplementary metabolic and endocrine influences have been discovered and investigated. The ever-expanding knowledge about the pathologic events that occur at disease inception enables us to explore new drugs and therapeutic approaches further and to test them using the same animal models. Discovery of the molecular targets that constitute the pathogenic basis of the disease along with scientific advancements allow us to target these molecules with monoclonal antibodies and other specific approaches directly. This novel therapy, termed 'targeted biological medication' is a promising endeavor towards producing drugs that are more effective and less toxic. Further work to discover additional molecular targets in lupus' pathogenic mechanism and to produce drugs that neutralize their activity is needed to provide patients with safe and efficient methods of controlling and treating the disease. © The Author(s), 2016. |
publishDate |
2017 |
dc.date.created.spa.fl_str_mv |
2017 |
dc.date.accessioned.none.fl_str_mv |
2020-05-25T23:56:51Z |
dc.date.available.none.fl_str_mv |
2020-05-25T23:56:51Z |
dc.type.eng.fl_str_mv |
article |
dc.type.coarversion.fl_str_mv |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
dc.type.coar.fl_str_mv |
http://purl.org/coar/resource_type/c_6501 |
dc.type.spa.spa.fl_str_mv |
Artículo |
dc.identifier.doi.none.fl_str_mv |
https://doi.org/10.1177/0961203317694261 |
dc.identifier.issn.none.fl_str_mv |
09612033 14770962 |
dc.identifier.uri.none.fl_str_mv |
https://repository.urosario.edu.co/handle/10336/22543 |
url |
https://doi.org/10.1177/0961203317694261 https://repository.urosario.edu.co/handle/10336/22543 |
identifier_str_mv |
09612033 14770962 |
dc.language.iso.spa.fl_str_mv |
eng |
language |
eng |
dc.relation.citationEndPage.none.fl_str_mv |
477 |
dc.relation.citationIssue.none.fl_str_mv |
No. 5 |
dc.relation.citationStartPage.none.fl_str_mv |
470 |
dc.relation.citationTitle.none.fl_str_mv |
Lupus |
dc.relation.citationVolume.none.fl_str_mv |
Vol. 26 |
dc.relation.ispartof.spa.fl_str_mv |
Lupus, ISSN:09612033, 14770962, Vol.26, No.5 (2017); pp. 470-477 |
dc.relation.uri.spa.fl_str_mv |
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85018348850&doi=10.1177%2f0961203317694261&partnerID=40&md5=764293029acc41b567156cc023ac7aca |
dc.rights.coar.fl_str_mv |
http://purl.org/coar/access_right/c_abf2 |
dc.rights.acceso.spa.fl_str_mv |
Abierto (Texto Completo) |
rights_invalid_str_mv |
Abierto (Texto Completo) http://purl.org/coar/access_right/c_abf2 |
dc.format.mimetype.none.fl_str_mv |
application/pdf |
dc.publisher.spa.fl_str_mv |
SAGE Publications Ltd |
institution |
Universidad del Rosario |
dc.source.instname.spa.fl_str_mv |
instname:Universidad del Rosario |
dc.source.reponame.spa.fl_str_mv |
reponame:Repositorio Institucional EdocUR |
repository.name.fl_str_mv |
Repositorio institucional EdocUR |
repository.mail.fl_str_mv |
edocur@urosario.edu.co |
_version_ |
1814167464810905600 |